The Gill Center’s General Hematology program is widely regarded as one of the country’s finest, largely on the merits of its long-standing commitment to research. Numerous professional articles in prestigious medical publications contributed by George Buchanan, M.D., and other staff members over the years have helped define and optimize treatment protocols for hematologic diseases in the U.S. and beyond. Their groundbreaking research includes extensive studies in immune thrombocytopenia and hereditary spherocytosis.
Immune thrombocytopenia (ITP): Substantial controversy has surrounded the treatment for children newly diagnosed with ITP, based largely on the toxicity and cost of medications used to treat the disorder because of fears of serious bleeding. Clinical researchers at Children’s published extensively on the management of ITP during childhood, emphasizing the relevance of outcome measures other than platelet count (e.g., bleeding signs and symptoms, cost of therapy and quality of life).
Hereditary spherocytosis: In a series of publications from 2007 to 2010, clinical researchers at Children’s defend the risks of vascular complications following splenectomy in patients with hereditary spherocytosis and other hemolytic anemias. The studies focus on the balance of potential benefits of hemolysis and anemia versus the deleterious effects of splenectomy in such patients.